Related Experiment Video
Updated: Jun 24, 2026
Methods for the Modulation and Analysis of NF-κB-dependent Adult Neurogenesis
Published on: February 13, 2014
Activation of GPR17 ameliorates neuroinflammation and improves neurological function via NF-κB pathway in an
Chenxi Guo1,2,3, Fengmei Zhou2,3, Chi Qin1,2
1Department of Radiology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Abstract:
Germinal matrix hemorrhage (GMH), a major complication of prematurity, involves severe neuroinflammation leading to neurological deficits. While G protein-coupled receptor 17 (GPR17) is known to modulate neuroinflammation, its therapeutic potential in GMH remains unexplored. This study investigated the anti-inflammatory effects and mechanisms of GPR17 activation in a neonatal rat GMH model induced by collagenase injection. Pre-treatment with the GPR17 agonist MDL-29951 was found to upregulate GPR17, downregulate cleaved Caspase-3, IL-1β, and TNF-α, and reduce apoptosis and glial infiltration at 1 day post-GMH. The treatment also improved neurological function, inhibited IκBα degradation and p65 nuclear translocation, and preserved white matter (WM) integrity. In vitro, GPR17 functioned as a negative regulator of the NF-κB pathway in primary microglia. These results suggest that GPR17 activation alleviates neuroinflammation and improves neurological outcomes after GMH, at least in part through attenuation of the NF‑κB pathway.
Insights
Activating G protein-coupled receptor 17 (GPR17) reduces neuroinflammation and brain injury in a neonatal rat model of germinal matrix hemorrhage (GMH). This therapeutic approach alleviates neurological deficits and preserves white matter integrity.
Area of Science:
- Neuroscience
- Developmental Biology
- Pharmacology
Background:
- Germinal matrix hemorrhage (GMH) is a significant complication of prematurity, often leading to severe neuroinflammation and long-term neurological deficits.
- G protein-coupled receptor 17 (GPR17) plays a role in modulating neuroinflammation, but its therapeutic utility in GMH has not been previously investigated.
Purpose of the Study:
- To investigate the anti-inflammatory effects and underlying mechanisms of GPR17 activation in a neonatal rat model of GMH.
- To explore the potential of GPR17 as a therapeutic target for mitigating GMH-induced brain injury.
Main Methods:
- A neonatal rat model of GMH was established using collagenase injection.
- Rats were pre-treated with the GPR17 agonist MDL-29951.
- Neuroinflammation markers (cleaved Caspase-3, IL-1β, TNF-α), apoptosis, glial infiltration, and white matter integrity were assessed.
- Neurological function was evaluated.
- In vitro studies using primary microglia examined the effect of GPR17 on the NF-κB pathway.
Main Results:
- MDL-29951 pre-treatment upregulated GPR17 expression and reduced cleaved Caspase-3, IL-1β, and TNF-α levels at 1 day post-GMH.
- The treatment decreased apoptosis and glial infiltration, while improving neurological function and preserving white matter (WM) integrity.
- GPR17 activation inhibited IκBα degradation and p65 nuclear translocation, indicating NF-κB pathway attenuation.
- In vitro, GPR17 acted as a negative regulator of the NF-κB pathway in primary microglia.
Conclusions:
- GPR17 activation demonstrates significant anti-inflammatory effects in the context of GMH.
- Targeting GPR17 may offer a novel therapeutic strategy to alleviate neuroinflammation and improve neurological outcomes in premature infants with GMH.
- The protective effects are, at least partly, mediated through the attenuation of the NF-κB signaling pathway.
